Catalyst Wire Dossier Catalyst Wire Dossier

AAV8 Factor IX gene therapy

AAV8-based factor IX gene therapy · Baxalta/Shire
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for AAV8 Factor IX gene therapy, covering 2026-03-20 to 2026-03-20. Get the full timeline:

Most recent: Clinical Trial Update: Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B [Phase 1, Phase 2]

See pricing